Fast track development of Ebola Vaccines

Primary tabs

Thu, 2015-01-15 16:44 — mike kraft

Principles and target product criteria

THE CENTER FOR INFECTIOUS DESEASE AND POLICY Jan 12, 2015

The unprecedented morbidity and mortality from the 2013- 2015 Ebola virus disease (EVD) epidemic in West Africa has challenged every aspect of our global ability to effectively detect, respond to, and control such a rapidly emerging infectious disease crisis.

As the epidemiology of the EVD epidemic has become more apparent over recent months, it is clear that

Ebola virus transmission can be reduced by employing traditional public health measures such as

contact tracing and infection control practices aimed at barrier protection. Nonetheless, the

potential for this epidemic to become an endemic situation, where ongoing virus transmission in

West Africa occurs in the foreseeable future, is a real and very concerning possibility.

As long as the Ebola virus continues to be transmitted to humans by humans in these countries, the potential for

sudden bursts of localized virus transmission will exist, and the risk of the Ebola virus expanding its range to other countries must be considered.

To support the ongoing international effort, the Wellcome Trust and the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota established an Ebola Vaccine Team B in November 2014. Team B was created to put fresh eyes on the same issues being addressed byvaccine manufacturers, government regulatoryauthorities, government public health agencies, non-governmental organizations, and global, national, and local leaders

Read complete report.
http://www.cidrap.umn.edu/sites/default/files/public/downloads/wellcome_trust-cidrap_ebola_vaccine_team_b_interim_report-final.pdf

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?: